Overview

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals